New anticancer agents.
Weiss
G R
GR
Arteaga
C L
CL
Brown
T D
TD
Craig
J B
JB
Harman
G S
GS
Koeller
J M
JM
Kuhn
J G
JG
Von Hoff
D D
DD
D000081:Acetamides / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005419:Flavonoids / Q000627:therapeutic use; D005708:Gallium / Q000627:therapeutic use; D006801:Humans; D008936:Mitolactol / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D015649:Pentostatin / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D012254:Ribavirin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016597:Trimetrexate; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives / Q000627:therapeutic use
D000081:Acetamides; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005419:Flavonoids; D009944:Organoplatinum Compounds; D011799:Quinazolines; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate; D015649:Pentostatin; D012254:Ribavirin; C049328:flavone acetic acid; D008942:Mitoxantrone; D005708:Gallium; C014026:hexamethylene bisacetamide; D008936:Mitolactol; C033706:tiazofurin; D016597:Trimetrexate; C027235:gallium nitrate